ARTICLE | Clinical News
MQX-503 regulatory update
June 30, 2008 7:00 AM UTC
FDA accepted for filing and granted Priority Review to an NDA from MediQuest for MQX-503 to treat Raynaud's disease. The PDUFA date is Oct. 28. MQX-503 is a topical gel formulation of nitroglycerin. ...